Astarte Medical is a technology company.
Astarte Medical has raised $8.0M across 1 funding round.
Astarte Medical has raised $8.0M in total across 1 funding round.
Astarte Medical was a health tech company founded in 2016 that developed digital tools, including the NICUtrition platform, to standardize feeding and nutrition protocols in neonatal intensive care units (NICUs), improving outcomes for preterm infants by addressing malnutrition, suboptimal growth, and care disparities.[1][2][4] It served hospitals and clinicians, focusing on the first 1,000 days of life from conception to age two, with AI-driven analytics for gut health, predictive modeling, and equitable care, while expanding to maternal risk identification and pediatric ICUs.[1][2][3] The company raised about $14 million across seed and Series A-1 rounds, secured four hospital clients like Arkansas Children’s Hospital and University of Virginia Children’s Hospital, but shut down after six years due to runway exhaustion amid slow hospital sales post-COVID, and began selling its assets including NICU software and gut health IP (three issued patents, one pending).[1][4][5]
Astarte Medical was co-founded in 2016 by Tracy Warren, who led the company as CEO, emerging from a focus on using data-driven digital tools to optimize NICU feeding and nutrition for premature babies.[1][4] The idea stemmed from recognizing gaps in preterm infant care, such as inconsistent protocols leading to prolonged hospital stays and IV nutrition dependency; early pivots addressed clinician burnout by adding monitoring and alerting features.[1] Key milestones included leading Technical.ly’s 2020 RealLIST Startups, participation in the 2022 Children’s Hospital of Los Angeles KidsX Accelerator (connecting to University of Virginia), onboarding Carilion Children’s Hospital in 2023, and a joint venture with Tiny Health for NICU gut health solutions using Astarte’s NICUbiome dataset.[1][3] With a small team of around seven employees, it grew deliberately, raising $7.6 million in Series A-1 funding in 2021 from investors like Viking Global Investors and Ben Franklin Technology Partners.[1][4]
Astarte rode the wave of AI-driven precision medicine in maternal-infant health, targeting underserved NICU gaps amid rising preterm births (affecting 10% of U.S. infants) and post-COVID emphasis on clinician tools to combat burnout and inequities.[1][2][5] Timing aligned with digital health acceleration, EMR adoption, and microbiome research booms, plus investor interest in pediatric tech via accelerators like KidsX.[1][3][4] It influenced the ecosystem by pioneering NICU nutrition intelligence, generating evidence on gut health protocols, and partnering for end-to-end solutions—pushing hospitals toward data-standardized care despite sales hurdles from procurement inertia.[1][3][5]
Astarte exemplifies health tech realities: strong tech, funding ($14M), and validation (four clients, publications) couldn't overcome slow NICU sales cycles and post-COVID hesitancy, leading to shutdown and asset sales of its valuable gut health IP.[5] Its legacy endures through patents and datasets likely acquired for broader microbiome applications in pediatrics or beyond, fueling trends like AI-EMR integration and infant precision nutrition. As acquirers integrate this tech, expect amplified impact on vulnerable populations, de-stigmatizing startup failures while advancing equitable NICU care—echoing Astarte's mission to transform preterm outcomes from day one.[3][5]
Astarte Medical has raised $8.0M in total across 1 funding round.
Astarte Medical's investors include Ben Franklin Technology Partners of Southeastern Pennsylvania.
Astarte Medical has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $8.0M Series A | Ben Franklin Technology Partners of Southeastern Pennsylvania |